Generic Name: elotuzumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Bristol-Myers Squibb

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

General Info

Empliciti is a monoclonal antibody that binds to the SLAMF7 receptor on myeloma cells. This helps immune cells known as natural killer cells recognize and attack the cancer.

Clinical trials showed that Empliciti slows progression of multiple myeloma.


Dosing Info:

Empliciti is administered as an intravenous infusion every week for the first two cycles, then every two weeks until disease progression occurs.

Side Effects

Common side effects include fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, decreased appetite and upper respiratory tract infections. It can cause birth defects and should not be used during pregnancy.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 18, 2018